LAVA’s GAMMABODY™ Platform
directly induces potent killing of tumor cells
via its unique targeting of Vγ9Vδ2 (Vgamma9 Vdelta2) T cells and tumor-associated antigens (TAAs).
via its unique targeting of Vγ9Vδ2 (Vgamma9 Vdelta2) T cells and tumor-associated antigens (TAAs).
They combine a variety of traits to accomplish this including:
Proof-of-principle of LAVA’s Gammabody™ approach has been established by in vitro, in vivo and ex vivo studies which demonstrate potent cell death in both tumor cell lines and patient-derived cells in both solid tumors and hematologic malignancies. Based on this data, LAVA has advanced its lead Gammabody™ drug candidates, LAVA-051 and LAVA-1207, into clinical development.